65,437 trials
Bipolar Depression
Primary: Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2) — 45.022; 32.472 units on scale
Alzheimer's Disease · Vascular Dementia
Primary: Change From Baseline in Mini Mental State Examination (MMSE) Total at Week 24 Last Observation Carried Forward (LOCF) — 1.92 Scores on a scale
Ulcerative Colitis
Primary: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 — 16.5; 9.3 Percentage of Participants — p=0.019
Prostatic Hyperplasia
Primary: AUC0-t — 237.35; 226.74 ng per hour per ml (ng/h/ml)
Myopia
Primary: Any Slit Lamp Finding > Grade 2 — 2; 5; 10 Eyes
Diabetic Neuropathies
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 11; 22; 126; 121 participants
Macular Edema Associated With Diabetes Mellitus
Primary: Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year — 49; 25 Participants — p=0.0047
Major Depressive Disorder · Hepatitis C, Chronic
Primary: Number of Participants Who Developed a Major Depressive Episode According to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During…
Healthy Volunteers
Primary: Mean Overnight Growth Hormone — 1.2 mcg/L — p=<0.005
Myelofibrosis
Primary: Number of Participants With Objective Clinical Response — 0; 1; 7; 26 Participants
Acquired Immunodeficiency Syndrome
Primary: Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h). — 99599; 73603; 45146 ng.h/mL — p=<0.05
Abscesses · Furunculosis · Staphylococcus Aureus
Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants Reporting at Least One Solicited Local or Systemic Reaction Post-Vaccination With ADACEL® Vaccine — 27; 27; 0; 1 Participants
Sleep Disorders · Obstructive Sleep Apnea · Major Depressive Disorder
Primary: Change From Baseline on Maintenance of Wakefulness Test (MWT) to Endpoint (12 Weeks or Last Observation After Baseline) — 2.6; 1.1 Minutes — p=0.3043